Close Menu

IQvia

Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.

IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.

Now a subsidiary of IQvia, NLP vendor Linguamatics also is looking to help precision medicine providers and pharma researchers with phenotype-genotype matching.

The new IQvia E360 Genomics build includes a "privacy-preserving" database system and will soon have analytic tools to support genotype-phenotype research.

CRO and analytics giant IQvia, the product of the IMS Health-Quintiles merger, quietly purchased UK-based bioinformatics company Linguamatics a month ago.

The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.

Under the terms of the agreement, Q2 Solutions will develop companion diagnostics on Illumina's MiSeqDx instrument.

In the second quarter, Quest reported revenues of $1.93 billion and estimated 2015 revenues will be between $7.49 billion and $7.57 billion.

The firms aim to establish the second largest lab services firm in the world to aid drugmakers with clinical trials.

The joint venture – of which Quintiles will own 60 percent and Quest will own 40 percent – is poised to be the second largest central laboratory services firm in the world.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.